Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

NCT04908228 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
53
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Paolo Ghia